Levemir Penfill

Insulin detemir, the active ingredient in Levemir Penfill, is a long‑acting insulin analog presented as an injectable solution (penfill) for subcutaneous use. It provides basal insulin coverage to treat diabetes mellitus in both type 1 and type 2 patients. GNH USA supplies Levemir Penfill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levemir Penfill is a long‑acting insulin analog used to manage blood glucose in diabetes mellitus. - Type 1 diabetes mellitus: provides basal insulin to maintain fasting glucose levels. - Type 2 diabetes mellitus: adds basal insulin when oral agents no longer achieve target glycaemia. - Adults requiring basal insulin therapy: offers once‑daily or twice‑daily dosing to support overall glucose control.

Levemir Penfill may cause a range of adverse reactions.

Common Side Effects: - Hypoglycaemia: low blood glucose episodes. - Injection site reactions: redness, swelling, or bruising. - Weight gain: increase in body weight over time. - Lipodystrophy: localized changes in fat tissue. - Edema: mild fluid retention. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Severe hypoglycaemia: potentially life‑threatening low glucose. - Anaphylactic reaction: rare allergic response requiring emergency care. - Serum insulin antibodies: may alter insulin effectiveness. - Hypokalemia: low potassium levels. - Severe skin necrosis at injection site. - Acute pancreatitis: rare inflammation of the pancreas.

Before using Levemir Penfill, consider the following precautions. - Dose adjustment: titrate based on glucose monitoring and clinical response. - Hypoglycaemia risk: educate patients on recognizing and treating low blood sugar. - Renal or hepatic impairment: may require lower doses and close monitoring. - Pregnancy and lactation: use only if benefits outweigh potential risks; consult a healthcare professional. - Concomitant medications: assess for agents that may mask hypoglycaemia or alter glucose levels. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levemir Penfill can interact with other medicines, affecting glucose control.

Major Interactions (Avoid): - Sulfonylureas or meglitinides: increased risk of severe hypoglycaemia. - Beta‑blockers: may mask hypoglycaemia symptoms. - Systemic glucocorticoids: can raise blood glucose, reducing insulin effectiveness.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may potentiate hypoglycaemia; monitor glucose. - Thiazide diuretics: can increase blood glucose; adjust insulin as needed. - Oral contraceptives: may slightly affect insulin requirements. - Alcohol: can cause unpredictable glucose fluctuations.